With the rapidly increasing drug discovery and sequential approvals, surging R&D initiatives, coupled with recent Fed rate cuts likely to encourage funding and investing, the biotech industry is positioned to experience solid growth. Also, advancements in technologies are swiftly accelerating the prospects of the market.
Given the industry’s positive prospects, it could be ideal to invest in fundamentally strong biotech stocks Amgen Inc. (AMGN), Regeneron Pharmaceuticals, Inc. (REGN), and Gilead Sciences, Inc. (GILD) with promising pipelines.
